Results 51 to 60 of about 39,610 (273)

Biomarkers of Cutaneous Leishmaniasis [PDF]

Frontiers in Cellular and Infection Microbiology, 2018
Cutaneous leishmaniasis (CL) is an immune-mediated skin pathology caused mainly by Leishmania (L.) major, Leishmania tropica, Leishmania braziliensis, L. mexicana, and L. amazonensis. The burden of CL in terms of morbidity and social stigmas are concentrated on certain developing countries in Asia, Africa, and South America. People with asymptomatic CL
Bahrami, Fariborz; Harandi, Ali M.; Riafati, Sima   +3 more
openaire   +3 more sources

The sandfly vectors and epidemiology of cutaneous leishmaniasis in the Landazury Focus, Colombia. [PDF]

This thesis describes a comprehensive cohort study of cutaneous leishmaniasis (CL) in a population of 2,704 followed over a period of 19 months, in the Opon focus, Landazury, Santander, Colombia.
Munoz-Mantilla, Gerardo
core   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Disseminated cutaneous leishmaniasis

Saudi Medical Journal, 2004
Disseminated cutaneous leishmaniasis DCL is a condition rarely seen in the Middle East. We report a case of disseminated cutaneous leishmaniasis in a 60-years-old lady. The patient first presented 1996 with an initial lesion, which started on the butterfly area of the face and spread, probably due to immunosuppression, to involve the whole face.
Khalifa E, Sharquie, Rafid A, Najim
openaire   +2 more sources

Structures, targets and recent approaches in anti-leishmanial drug discovery and development. [PDF]

, 2011
Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002.
Karin Seifert, Seifert, Karin
core   +1 more source

Recombinant LPG3 Protein From Leishmania chagasi as an Antigen for the Diagnosis of Canine Visceral Leishmaniasis

Tropical Medicine &International Health, EarlyView.
ABSTRACT Visceral leishmaniasis (VL) is a human neglected tropical disease in which dogs participate as reservoirs of the etiological agent Leishmania chagasi. The identification of infected dogs is important to the control of VL, and recombinant proteins are strong antigen candidates for canine visceral leishmaniasis (CVL) serodiagnosis. In this work,
Thaís Viana Fialho Martins, Anna Cláudia Alves de Souza, Bianca Meireles Miranda, Ronny Francisco de Souza, Daniel Silva Sena Bastos, Neverton José Silva Ferreira, Tiago Antônio de Oliveira Mendes, Celeste da Silva Freitas de Souza, George Luiz Lins Machado‐Coelho, Maria Terezinha Bahia, Leandro Licursi de Oliveira, Juliana Lopes Rangel Fietto, Eduardo de Almeida Marques‐da‐Silva   +12 more
wiley   +1 more source

The prolonged epidemic of anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: 'bringing down the neighbourhood'. [PDF]

, 2003
In order to investigate the distribution and causes of the spread of anthroponotic cutaneous leishmaniasis (ACL) in Kabul, Afghanistan, a cross-sectional study was conducted during 1997-98 amongst 75,787 residents in the 13 central districts of the city.
Rowland, Mark, Davies, Clive, Khan, Bismulla, Reyburn, Hugh, Mohsen, Mohammmed   +4 more
core   +1 more source

The Effect of Local Allergic Reaction to Intralesional Glucantime on Recovery Course of Cutaneous Leishmaniasis

مجله دانشکده پزشکی اصفهان, 2020
Background: Systemic or intralesional injection of Glucantime in treatment of cutaneous leishmaniasis, sometimes leads to a local allergic reaction.
Saman Afkhami-Ardakani, Vahid Mashayekhi-Goyonlo, Bita Kiafar, Reza Mortezaei, Yahya Shahrokhi   +4 more
doaj   +1 more source

Addressing Behavioural Determinants of Cutaneous Leishmaniasis Through Community Dialogue in Kalu District, Ethiopia: A Mixed‐Methods Study

Tropical Medicine &International Health, EarlyView.
ABSTRACT Background Cutaneous leishmaniasis (CL) is a major public health challenge in Ethiopia, with 20–30,000 new cases annually. Limited awareness and misconceptions contribute to delayed care seeking, stigma, prolonged healing, and reduced uptake of preventive measures in CL‐endemic communities.
Takele Gezahegn Demie, Tara Mtuy, Jennifer Palmer, Eshetu Girma, Yohannes Hailemichael, Teklu Cherkose, Telahun Kasa Tefera, Mohammedjud Hassen Ahmed, Catherine Pitt, Michael Marks, Stephen L. Walker, Endalamaw Gadisa, Mirgissa Kaba, SHARP collaboration   +13 more
wiley   +1 more source

Efficacy of Thermotherapy to Treat Cutaneous Leishmaniasis Caused by Leishmania tropica in Kabul, Afghanistan: A Randomized, Controlled Trial [PDF]

, 2005
BACKGROUND: Pentavalent antimony is the agent recommended for treatment of cutaneous leishmaniasis (CL). Its use is problematic, because it is expensive and because of the potential for drug-associated adverse effects during a lengthy and painful ...
Davies, C.R., Reithinger, R, Quinnell, RJ, Quinnell, R.J., Bismullah, M, Davies, CR, David, J.R., Reithinger, R., Mohsen, M., Wahid, M., Bismullah, M., Wahid, M, David, JR, Kolaczinski, J., Kolaczinski, J, Mohsen, M   +15 more
core   +1 more source